Tumour regression after endostatin therapy

Article metrics

Abstract

It was with great interest that we read the report1 on the lack of acquired drug resistance to repeated doses of endostatin in experimental cancers in mice. Of particular interest is the unprecedented finding that each tumour type became indefinitely dormant after a varying number of treatment cycles. We believe one explanation for this phenomenon might be found in the clinical observation that, after complete regression of large bulky tumours, rebiopsy of the primary tumour site will frequently show large amounts of fibrosis or scarring.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1

    Boehm, T.et al. Nature 390, 404–407 (1997).

Download references

Author information

Rights and permissions

Reprints and Permissions

About this article

Further reading

Comments

By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.